HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

tetomilast

Also Known As:

6-(2-(3,4-diethoxyphenyl)thiazol-4-yl)-pyridine-2-carboxylic acid; OPC 6535; OPC-6535; OPC6535

Networked: 9 relevant articles (1 outcomes, 4 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Sulfur Compounds: 278
  - Thiazoles: 392
    - tetomilast: 9
Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Thiazoles: 392
      - tetomilast: 9

Experts

1.	Nagamoto, Hisashi: 2 articles (01/2012 - 11/2008)
2.	Song, Shun-de: 1 article (01/2014)
3.	Tang, Hui-fang: 1 article (01/2014)
4.	Bickston, Stephen J: 1 article (12/2012)
5.	Kappus, Matthew R: 1 article (12/2012)
6.	Snider, Kenneth R: 1 article (12/2012)
7.	Abdollahi, Mohammad: 1 article (03/2012)
8.	Salari, Pooneh: 1 article (03/2012)
9.	Baila, Bulin: 1 article (01/2012)
10.	Endo, Junki: 1 article (01/2012)

Related Diseases

1.	Acute Lung Injury 09/01/1997 - "Treatment of animals with OPC-6535 prior to the onset of sepsis produced significant protection against acute lung injury but failed to attenuate hemodynamic derangements associated with sepsis." 09/01/1997 - "Treatment with OPC-6535 significantly reduced acute lung injury, as indicated by improved bronchoalveolar lavage protein and neutrophil content, resulting in a significant improvement in arterial oxygenation. " 09/01/1997 - "OPC-6535, a superoxide anion production inhibitor, attenuates acute lung injury." 09/01/1997 - "The present study sought to evaluate the ability of OPC-6535, a superoxide anion production inhibitor, to attenuate sepsis-induced acute lung injury. "
2.	Sepsis (Septicemia) 09/01/1997 - "Treatment of animals with OPC-6535 prior to the onset of sepsis produced significant protection against acute lung injury but failed to attenuate hemodynamic derangements associated with sepsis." 09/01/1997 - "The present study sought to evaluate the ability of OPC-6535, a superoxide anion production inhibitor, to attenuate sepsis-induced acute lung injury. "
3.	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 11/01/2008 - "In this study we aimed to examine whether tetomilast could be a novel drug for inflammatory bowel diseases by further clarifying its antiinflammatory effects. " 11/01/2008 - "Combined with in vivo data these findings support the feasibility of tetomilast as a novel drug for inflammatory bowel diseases." 12/01/2012 - "Tetomilast is a novel thiazole phosphodiesterase-4 (PDE-4) inhibitor, which may prove useful in both the treatment of inflammatory bowel disease (IBD) and chronic obstructive pulmonary disease (COPD). " 01/01/2014 - "The efficacy and safety evaluations of several PDE4 inhibitors are currently carried on in clinical trials, for example GSK256066 in asthma, roflumilast and GSK256066 in chronic obstructive pulmonary disease, tetomilast in inflammatory bowel disease, and apremilast in dermatitis and arthritis etc. This article reviews the recent progress on PDE4-targeted therapy for inflammatory diseases."
4.	Chronic Obstructive Pulmonary Disease (COPD) 01/01/2012 - "Tetomilast was originally identified as a potent inhibitor of superoxide production in human neutrophils, and is of interest because it may relieve oxidative stress related to chronic obstructive pulmonary disease (COPD). " 06/01/2005 - "Otsuka is developing a once-daily oral formulation of the phosphodiesterase-4 inhibitor tetomilast for the potential treatment of ulcerative colitis (phase III) and chronic obstructive pulmonary disease (phase II)." 12/01/2012 - "Tetomilast is a novel thiazole phosphodiesterase-4 (PDE-4) inhibitor, which may prove useful in both the treatment of inflammatory bowel disease (IBD) and chronic obstructive pulmonary disease (COPD). " 01/01/2014 - "The efficacy and safety evaluations of several PDE4 inhibitors are currently carried on in clinical trials, for example GSK256066 in asthma, roflumilast and GSK256066 in chronic obstructive pulmonary disease, tetomilast in inflammatory bowel disease, and apremilast in dermatitis and arthritis etc. This article reviews the recent progress on PDE4-targeted therapy for inflammatory diseases."
5.	Ulcerative Colitis 01/01/2007 - "This phase II trial of tetomilast in ulcerative colitis did not achieve statistical significance for the primary end point. " 01/01/2007 - "A randomized, placebo-controlled, phase II study of tetomilast in active ulcerative colitis." 01/01/2007 - "One hundred eighty-six patients with mildly to moderately active ulcerative colitis (Disease Activity Index [DAI] 4-11 points) from 35 centers were randomized to receive an oral, once-daily dose of placebo or tetomilast 25 mg or 50 mg for 8 weeks. " 06/01/2005 - "Otsuka is developing a once-daily oral formulation of the phosphodiesterase-4 inhibitor tetomilast for the potential treatment of ulcerative colitis (phase III) and chronic obstructive pulmonary disease (phase II)."

Related Drugs and Biologics

1.	Proteins (Proteins, Gene)
2.	Superoxides (Superoxide)
3.	Roflumilast
4.	Phosphodiesterase 4 Inhibitors
5.	6- ((3- ((dimethylamino)carbonyl)phenyl)sulfonyl)- 8- methyl- 4- ((3- methyloxyphenyl)amino)- 3- quinolinecarboxamide
6.	apremilast
7.	Type 4 Cyclic Nucleotide Phosphodiesterases
8.	tetomilast
9.	Dexlansoprazole
10.	Esomeprazole (Nexium)

Related Therapies and Procedures

1.	Therapeutics